clotrimazole inhibits the recombinant human cardiac l-type

  • clotrimazole inhibits the recombinant human cardiac l-type

    Clotrimazole inhibits the recombinant human cardiac L-type

    Clotrimazole (CLT) is an antimycotic agent with a potential role in the treatment of cancer. Whole-cell patch clamp recordings and Fura-2 AM fluorescence measurements were used to investigate the inhibition by CLT of recombinant human cardiac L-type Ca 2+ channel α 1C subunits, stably expressed in human embryonic kidney (HEK 293) cells.

  • clotrimazole inhibits the recombinant human cardiac l-type

    Clotrimazole inhibits the recombinant human cardiac L-type

    Clotrimazole (CLT) is an antimycotic agent with a potential role in the treatment of cancer. Whole-cell patch clamp recordings and Fura-2 AM fluorescence measurements were used to investigate the inhibition by CLT of recombinant human cardiac L-type Ca2+ channel alpha 1C subunits, stably expressed in human embryonic kidney (HEK 293) cells.

  • clotrimazole inhibits the recombinant human cardiac l‐type

    Clotrimazole inhibits the recombinant human cardiac L‐type

    Clotrimazole (CLT) is an antimycotic agent with a potential role in the treatment of cancer. Whole‐cell patch clamp recordings and Fura‐2 AM fluorescence measurements were used to investigate the inhibition by CLT of recombinant human cardiac L‐type Ca 2+ channel α 1C subunits, stably expressed in human embryonic kidney (HEK 293) cells.

  • clotrimazole inhibits the recombinant human cardiac l‐type

    Clotrimazole inhibits the recombinant human cardiac L‐type

    Request PDF | Clotrimazole inhibits the recombinant human cardiac L‐type Ca2+ channel α1C subunit | Clotrimazole (CLT) is an antimycotic agent with a potential role in the treatment of cancer.

  • clotrimazole inhibits the recombinant human cardiac l-type

    Clotrimazole inhibits the recombinant human cardiac L-type

    Abstract. Clotrimazole (CLT) is an antimycotic agent with a potential role in the treatment of cancer. Whole-cell patch clamp recordings and Fura-2 AM fluorescence measurements were used to investigate the inhibition by CLT of recombinant human cardiac L-type Ca2+ channel α1C subunits, stably expressed in human embryonic kidney (HEK 293) cells.CLT (100 nmol l−1 to 25 μmol l−1) reduced

  • the antifungal antibiotic clotrimazole potently inhibits l

    The antifungal antibiotic clotrimazole potently inhibits L

    I M Fearon, S G Ball, C Peers, Clotrimazole inhibits the recombinant human cardiac L‐type Ca2+ channel α1C subunit, British Journal of Pharmacology, 10.1038/sj.bjp.0703106, 129, 3, (547-554), (2009).

  • inhibition of trpm2 channels by the antifungal agents

    Inhibition of TRPM2 channels by the antifungal agents

    Fearon IM, Ball SG, Peers C (2000) Clotrimazole inhibits the recombinant human cardiac L-type Ca2+ channel alpha 1C subunit. Br J Pharmacol 129:547–554 PubMed Google Scholar Fonfria E, Marshall ICB, Benham CD, Boyfield I, Brown JB, Hill K, Hughes JP, Skaper SD, McNulty S (2004) TRPM2 channel opening in response to oxidative stress is

  • effects of the antifungal antibiotic clotrimazole on human

    Effects of the antifungal antibiotic clotrimazole on human

    The antifungal antibiotic clotrimazole (CLT) shows therapeutic effects on cancer, sickle cell disease, malaria, etc. by inhibiting membrane intermediate-conductance Ca2+-activated K+ channels (IKCa).

  • effects of the antifungal antibiotic clotrimazole on human

    Effects of the antifungal antibiotic clotrimazole on human

    1. The antifungal antibiotic clotrimazole (CLT) shows therapeutic effects on cancer, sickle cell disease, malaria, etc. by inhibiting membrane intermediate-conductance Ca 2+-activated K + channels (IK Ca). However, it is unclear whether this drug would affect human cardiac K + currents.

  • (pdf) sexually dimorphic response of trpm2 inhibition

    (PDF) Sexually Dimorphic Response of TRPM2 Inhibition

    Fearon IM, Ball SG et al (2000) Clotrimazole inhibits the recombinant. human cardiac L-type Ca2+ channel alpha 1C subunit. Br J. Pharmacol 129(3)

  • inhibition of recombinant human cardiac l-type ca2+ channel

    Inhibition of recombinant human cardiac L-type Ca2+ channel

    3. Results. All data presented here were obtained from a clonal line of HEK 293 cells in which the human cardiac L-type Ca 2+ channel α 1C subunit was stably expressed. These currents were increased in amplitude by bath application of Bay K 8644 (2 μM) and fully inhibited by nifedipine (2 μM), indicating that all currents arose from activation of recombinant L-type Ca 2+ channel subunits

  • cacna1s haploinsufficiency confers resistance to - pnas.org

    CACNA1S haploinsufficiency confers resistance to - pnas.org

    It is well known that genetic differences among individuals can influence their susceptibility to infectious disease. Our results, using New World arenavirus-infected mice heterozygous for the α1S chain of the VGCC, human cells heterozygous for a mutation of this chain, and drugs that target this receptor, highlight the influence of genetic background on the outcome of infection and zoonoses.